## RMD: ResMed Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -3.6% below STRENGTH zone (4.0-10.0%); PEG 1.86 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($234.42)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. ResMed Inc announces proposed sale of securities by director**
- Source: MSN | 20251207T190945 | Neutral | Relevance: 98%
-  This article from MSN reports on ResMed Inc's announcement regarding a proposed sale of securities by one of its directors. No further details are provided in the snippet.

**2. Resmed (NYSE: RMD) gets FDA clearance for AI Smart Comfort built on 100M sleep nights**
- Source: Stock Titan | 20251208T140241 | Bullish | Relevance: 98%
-  Resmed (NYSE: RMD) has received FDA clearance for its AI-enabled Smart Comfort, a digital medical device designed to personalize CPAP comfort settings. Utilizing machine learning trained on over 100 million nights of de-identified sleep data, Smart Comfort aims to improve patient engagement and adherence to CPAP therapy for obstructive sleep apnea. A limited U.S. beta launch is planned for early 2026, with a broader rollout later the same year.

**3. Resmed wins FDA clearance for AI-enabled personalized CPAP therapy device**
- Source: MassDevice | 20251208T145057 | Bullish | Relevance: 98%
-  Resmed (NYSE: RMD) has received FDA clearance for its Smart Comfort personalized therapy comfort settings (PTCS), an AI-enabled medical device designed to recommend personalized CPAP comfort settings for individuals with obstructive sleep apnea. This technology, which uses proprietary machine learning algorithms and real-world sleep data, aims to improve therapy adherence and streamlines clinician workflows. A limited U.S. beta rollout targeting new myAir app users with the AirSense 11 device is planned for early next year, followed by a broader U.S. rollout later in 2026.

**4. Is ResMed Stock Underperforming the S&P 500?**
- Source: Markets Financial Content | 20251208T085800 | Neutral | Relevance: 98%
-  ResMed Inc. (RMD) has underperformed the S&P 500 year-to-date and over the past year, despite strong Q1 2026 results and analyst optimism. The medical device company, specializing in respiratory disorders, has seen its stock decline by 7.4% over the past three months, while the S&P 500 increased by 6%. Analysts maintain a “Moderate Buy” rating with a premium price target.

**5. Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy**
- Source: KFOR | 20251209T020952 | Bullish | Relevance: 97%
-  Resmed has received FDA clearance for Smart Comfort, an AI-enabled medical device designed to personalize CPAP therapy for individuals with obstructive sleep apnea (OSA). This technology uses machine learning and real-world sleep data to recommend individualized comfort settings, aiming to improve therapy adherence and patient experience. Smart Comfort is set to launch as a limited beta in early 2026, with a broader rollout later that year.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 18 ($9.51M) |
| Sells | 14 ($4.85M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 13.1% (+1.6%)
- Blackrock Inc.: 8.4% (-1.3%)
- State Street Corpora: 4.5% (-1.0%)
- Bank Of New York Mel: 3.1% (-9.8%)
- Geode Capital Manage: 2.9% (+0.9%)

### Key Risks

1. Insider selling cluster: $4.9M in recent transactions.
2. Elevated short interest (8.4%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.86 elevated, pricing in significant growth expectations. Forward P/E 20.5x stretched relative to 10% growth. Quality metrics strong (ROE 25%, ROA 14%, margin 27%). Balance sheet: strong liquidity (2.9x), low leverage (D/E 0.36). Institutional flow bullish (3 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $36.0B |
| Beta | 0.87 |
| 52W Range | $199.92 - $293.81 |
| Short Interest | 8.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.86 |
| Forward P/E | 20.5 |
| Current P/E | 22.6 |
| YoY Growth | 10.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -1.2% to -3.6% (-2.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.6pp (needs >4.0% for momentum thesis). Below SMA200 (0.97x), long-term trend not supportive. MACD histogram positive (0.54), confirming momentum. RSI neutral at 42.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.58% (CS: 30) | Weak |
| RSI_14 | 41.8 | Neutral |
| MACD Histogram | 0.54 | Bullish |
| vs SMA20 | 0.985x | Below |
| vs SMA50 | 0.952x | Below |
| vs SMA200 | 0.975x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $246.52
- **Stop Loss:** $234.42 (4.9% risk)
- **Target:** $258.62 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 24
- **Position Value:** $5,916.48
- **Portfolio %:** 5.92%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-05 (Est: $2.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.55 | +2.0% |
| 2025Q2 | $2.48 | $2.55 | +2.8% |
| 2025Q1 | $2.36 | $2.37 | +0.4% |
| 2024Q4 | $2.31 | $2.43 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*